vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and OneSpan Inc. (OSPN). Click either name above to swap in a different company.
OneSpan Inc. is the larger business by last-quarter revenue ($65.9M vs $62.1M, roughly 1.1× Cytek Biosciences, Inc.). OneSpan Inc. runs the higher net margin — 17.5% vs -70.9%, a 88.5% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 4.1%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 4.0%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
OneSpan Inc. is an information security company based in Boston, Massachusetts. Services include an internet fraud prevention platform, multi-factor authentication tools and electronic signature software.
CTKB vs OSPN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $65.9M |
| Net Profit | $-44.1M | $11.6M |
| Gross Margin | 52.9% | 73.6% |
| Operating Margin | -9.0% | 22.5% |
| Net Margin | -70.9% | 17.5% |
| Revenue YoY | 8.1% | 4.1% |
| Net Profit YoY | -557.1% | — |
| EPS (diluted) | — | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $65.9M | ||
| Q4 25 | $62.1M | $62.9M | ||
| Q3 25 | $52.3M | $57.1M | ||
| Q2 25 | $45.6M | $59.8M | ||
| Q1 25 | $41.5M | $63.4M | ||
| Q4 24 | $57.5M | $61.2M | ||
| Q3 24 | $51.5M | $56.2M | ||
| Q2 24 | $46.6M | $60.9M |
| Q1 26 | — | $11.6M | ||
| Q4 25 | $-44.1M | $43.5M | ||
| Q3 25 | $-5.5M | $6.5M | ||
| Q2 25 | $-5.6M | $8.3M | ||
| Q1 25 | $-11.4M | $14.5M | ||
| Q4 24 | $9.6M | $28.8M | ||
| Q3 24 | $941.0K | $8.3M | ||
| Q2 24 | $-10.4M | $6.6M |
| Q1 26 | — | 73.6% | ||
| Q4 25 | 52.9% | 73.6% | ||
| Q3 25 | 52.7% | 73.6% | ||
| Q2 25 | 52.3% | 73.5% | ||
| Q1 25 | 48.6% | 74.3% | ||
| Q4 24 | 58.5% | 74.0% | ||
| Q3 24 | 56.3% | 73.9% | ||
| Q2 24 | 54.6% | 66.2% |
| Q1 26 | — | 22.5% | ||
| Q4 25 | -9.0% | 19.9% | ||
| Q3 25 | -17.6% | 14.4% | ||
| Q2 25 | -23.3% | 17.6% | ||
| Q1 25 | -36.1% | 27.1% | ||
| Q4 24 | 5.2% | 19.3% | ||
| Q3 24 | -8.2% | 20.0% | ||
| Q2 24 | -18.3% | 12.5% |
| Q1 26 | — | 17.5% | ||
| Q4 25 | -70.9% | 69.2% | ||
| Q3 25 | -10.5% | 11.4% | ||
| Q2 25 | -12.2% | 13.9% | ||
| Q1 25 | -27.5% | 22.9% | ||
| Q4 24 | 16.8% | 47.1% | ||
| Q3 24 | 1.8% | 14.7% | ||
| Q2 24 | -22.4% | 10.8% |
| Q1 26 | — | $0.39 | ||
| Q4 25 | — | $1.13 | ||
| Q3 25 | — | $0.17 | ||
| Q2 25 | — | $0.21 | ||
| Q1 25 | — | $0.37 | ||
| Q4 24 | — | $0.73 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $49.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $272.0M |
| Total Assets | $461.5M | $383.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $49.8M | ||
| Q4 25 | $90.9M | $70.5M | ||
| Q3 25 | $93.3M | $85.6M | ||
| Q2 25 | $75.5M | $92.9M | ||
| Q1 25 | $95.3M | $105.2M | ||
| Q4 24 | $98.7M | $83.2M | ||
| Q3 24 | $162.3M | $77.5M | ||
| Q2 24 | $177.9M | $63.8M |
| Q1 26 | — | $272.0M | ||
| Q4 25 | $341.7M | $271.8M | ||
| Q3 25 | $378.6M | $238.3M | ||
| Q2 25 | $377.6M | $242.5M | ||
| Q1 25 | $379.6M | $231.1M | ||
| Q4 24 | $395.7M | $212.5M | ||
| Q3 24 | $385.5M | $194.6M | ||
| Q2 24 | $389.1M | $178.6M |
| Q1 26 | — | $383.1M | ||
| Q4 25 | $461.5M | $397.7M | ||
| Q3 25 | $494.9M | $343.5M | ||
| Q2 25 | $493.3M | $357.1M | ||
| Q1 25 | $482.6M | $333.8M | ||
| Q4 24 | $499.5M | $338.7M | ||
| Q3 24 | $491.2M | $289.3M | ||
| Q2 24 | $483.7M | $286.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $28.2M |
| Free Cash FlowOCF − Capex | $-1.8M | — |
| FCF MarginFCF / Revenue | -2.9% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | — | 2.44× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $28.2M | ||
| Q4 25 | $-771.0K | $12.6M | ||
| Q3 25 | $-3.9M | $11.3M | ||
| Q2 25 | $108.0K | $6.2M | ||
| Q1 25 | $-125.0K | $29.4M | ||
| Q4 24 | $2.0M | $12.4M | ||
| Q3 24 | $13.2M | $14.0M | ||
| Q2 24 | $6.2M | $2.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-1.8M | $9.6M | ||
| Q3 25 | $-4.6M | $8.8M | ||
| Q2 25 | $-1.5M | $4.4M | ||
| Q1 25 | $-974.0K | $27.7M | ||
| Q4 24 | $1.1M | $10.5M | ||
| Q3 24 | $12.2M | $12.0M | ||
| Q2 24 | $5.2M | $26.0K |
| Q1 26 | — | — | ||
| Q4 25 | -2.9% | 15.3% | ||
| Q3 25 | -8.7% | 15.4% | ||
| Q2 25 | -3.2% | 7.3% | ||
| Q1 25 | -2.3% | 43.8% | ||
| Q4 24 | 1.9% | 17.1% | ||
| Q3 24 | 23.7% | 21.4% | ||
| Q2 24 | 11.0% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.6% | 4.7% | ||
| Q3 25 | 1.3% | 4.4% | ||
| Q2 25 | 3.5% | 3.1% | ||
| Q1 25 | 2.0% | 2.6% | ||
| Q4 24 | 1.6% | 3.2% | ||
| Q3 24 | 2.0% | 3.5% | ||
| Q2 24 | 2.3% | 3.7% |
| Q1 26 | — | 2.44× | ||
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | 1.74× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | 0.21× | 0.43× | ||
| Q3 24 | 14.05× | 1.69× | ||
| Q2 24 | — | 0.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
OSPN
| Product and license | $35.5M | 54% |
| Services and other | $30.4M | 46% |
